Novavax (NVAX) is awaiting the outcome of a June 7 meeting of the FDA’s vaccine advisory committee, which could finally bring its COVID-19 vaccine to the U.S. market.
Chief Commercial Officer John Trizzino told Yahoo Finance in an exclusive interview Wednesday that the company is optimistic about the upcoming meeting.
Novavax ran into manufacturing quality problems in early 2021 and experienced subsequent delays in its Phase 3 trial in the U.S., forcing the company to push back its timeline…
Source link
